We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
27 Oct 2021 - 29 Oct 2021

Differential Biochemical Markers Identified in Inflammatory Processed Synovial Fluid

By LabMedica International staff writers
Posted on 28 Jul 2021
Print article
Image: The AU5800 Clinical Chemistry Analyzer is an automated chemistry analyzer that measures many different chemical analytes (Photo courtesy of Beckman Coulter)
Image: The AU5800 Clinical Chemistry Analyzer is an automated chemistry analyzer that measures many different chemical analytes (Photo courtesy of Beckman Coulter)
Joint infections with a non-specific presentation are difficult to diagnose, mainly due to the absence of specific clinical signs and symptoms, relative lack of accurate laboratory tests, low virulence due to previous treatment, and biofilm ability of the pathogens.

This difficulty is especially true for patients treated with non-targeted antibiotics, including patients with implanted joint replacements. New biochemical markers are being sought to help quickly determine the extent of the inflammatory process taking place in the joint cavity in routine biochemical practice, either due to its increased concentration in synovial fluid (SF) or directly in serum/plasma.

Clinical Biochemists and their colleagues at the University of Ostrava (Ostrava, Czech Republic) sought to identify biochemical markers in Synovial Fluid (SF) that can predict susceptibility to ongoing inflammatory processes in the joint cavity. Ninety-two consecutive patients were divided into four SF groups based on clustering analysis: non-inflammatory SF (73%), inflammatory-non-pyogenic (12%), inflammatory-pyogenic (10%), or hemorrhagic (5%).

The team measured and compared the levels of the following biochemical markers in SF: glucose, lactate, total protein, uric acid, C-Reactive Protein (CRP), Leukocyte Count (WBC), Mononuclear (MNP), Polymorphonuclear (PMN), Interleukin (IL)-1 beta, IL6, Procalcitonin, Presepsin, Neutrophil Gelatinase-Associated Lipocalin (NGAL), Human Neutrophil Defensin 1-3 (HNP1-3), Cartilage Oligomeric Matrix Protein, Lactoferrin (HLF2), Polymorphonuclear Elastase (PMNE), Matrix Metalloproteinase (MMP)-1, and MMP-3. The concentrations of the biochemical biomarkers were determined on an AU 5800 automated analyzer (Beckman Coulter, Brea, CA, USA). They analyzed hematological parameters, relative and absolute numbers of leukocytes (WBC), and (MNP) and PMN leukocyte counts on a XN-9000 Automated in Body Fluid mode (Sysmex, Kobe, Japan).

The scientists reported that a significant difference between WBC, PMN, MNP, CRP, IL-1β, IL-6, HNP1-3, HLF2, PMNE, and individual groups of SF type. They also found a significant correlation between WBC and PMN, MNP, and CRP; PMN and HNP1-3 and PMNE; IL-6 and PMNE; IL-1β and NGAL, HLF2, and PMNE; HNP1-3 and NGAL, HLF2, and PMNE; NGAL and HLF2 and PMNE; and HLF2 and PMNE concentrations in all SF groups, between WBC and MNP; IL-1β and NGAL and MMP-3; HNP1-3 and PMNE; and NGAL and HLF2 concentrations in the non-inflammatory SF group, and between PMN and MNP in the inflammatory-non-pyogenic and inflammatory-pyogenic SF groups. PMN, MNP, WBC, CRP, and HNP1-3 in SF predicted the inflammatory processes with excellent diagnostic performance.

The authors concluded that SF biomarkers WBC, PMN, MNP CRP, HNP1-3, IL-1, IL-6, PMNE, and HLF2 allow the classification of new patients into the relevant SF group with an accuracy of 94.4%. In addition, WBC, PMN, MNP, CRP, and HNP1-3 provide excellent diagnostic sensitivity and specificity for the diagnosis of infection, despite the study including a limited number of patients with pyogenic and non-pyogenic inflammation. The study was originally published on line on March 15, 2021 in the Journal of Clinical Chemistry and Laboratory Medicine.

Related Links:
University of Ostrava
Beckman Coulter
Sysmex


New
Gold Supplier
BMP Whole Blood Analyzer
GEM Premier ChemSTAT
New
6-Channel Viscoelastometry Analyzer
ClotPro
New
Modular Syndromic Testing System
QIAstat-Dx (DiagCORE) Analyzer
New
Molecular Diagnostic Platform
VERIGENE II System

Print article

Channels

Hematology

view channel
Image: Psoriatic plaques, showing a silvery center surrounded by a reddened border (Photo courtesy of Jane Bianchi, BA)

Hematological Parameters Compared in Psoriasis Patients

Psoriasis is a chronic, immune-mediated disorder that can involve the skin and/or joints. Four clinical types of psoriasis are currently recognized: psoriasis vulgaris (PsV), pustular psoriasis (PP), erythrodermic... Read more

Microbiology

view channel
Illustration

Sysmex Inostics Launches New Ultra-Sensitive Leukemia Blood Test for Early Detection of Cancer Cells Following Initial Therapy

Sysmex Inostics (Baltimore, MD, USA) has developed a new CLIA-validated liquid biopsy test for the detection of Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML) to better help in the fight... Read more

Technology

view channel
Image: QIAreach QuantiFERON-TB (Photo courtesy of QIAGEN N.V.)

Qiagen Launches Novel Tuberculosis Blood Test That Marks Quantum Leap from Traditional TB Skin Test

QIAGEN N.V. (Venlo, Netherlands) has announced the launch and CE marking of QIAreach QuantiFERON-TB test for tuberculosis (TB) infection, in order to help achieve global TB elimination targets by increasing... Read more

Industry

view channel
Image: GastroPanel Quick Test (Photo courtesy of Biohit Healthcare)

Biohit’s Innovative GastroPanel Quick Test Receives CE Mark

Biohit Healthcare’s (Helsinki, Finland) GastroPanel Quick Test, the latest innovation in its unique GastroPanel product family, is now CE marked. The GastroPanel Quick Test is intended for diagnosing... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.